Literature DB >> 19300998

Influence of multidrug resistance on (18)F-FCH cellular uptake in a glioblastoma model.

Claire Vanpouille1, Nathalie Le Jeune, David Kryza, Anthony Clotagatide, Marc Janier, Francis Dubois, Nathalie Perek.   

Abstract

PURPOSE: Multidrug resistance, aggressiveness and accelerated choline metabolism are hallmarks of malignancy and have motivated the development of new PET tracers like (18)F-FCH, an analogue of choline. Our aim was to study the relationship of multidrug resistance of cultured glioma cell lines and (18)F-FCH tracer uptake.
METHODS: We used an in vitro multidrug-resistant (MDR) glioma model composed of sensitive parental U87MG and derived resistant cells U87MG-CIS and U87MG-DOX. Aggressiveness, choline metabolism and transport were studied, particularly the expression of choline kinase (CK) and high-affinity choline transporter (CHT1). FCH transport studies were assessed in our glioblastoma model.
RESULTS: As expected, the resistant cell lines express P-glycoprotein (Pgp), multidrug resistance-associated protein isoform 1 (MRP1) and elevated glutathione (GSH) content and are also more mobile and more invasive than the sensitive U87MG cells. Our results show an overexpression of CK and CHT1 in the resistant cell lines compared to the sensitive cell lines. We found an increased uptake of FCH (in % of uptake per 200,000 cells) in the resistant cells compared to the sensitive ones (U87MG: 0.89 +/- 0.14; U87MG-CIS: 1.27 +/- 0.18; U87MG-DOX: 1.33 +/- 0.13) in line with accelerated choline metabolism and aggressive phenotype.
CONCLUSIONS: FCH uptake is not influenced by the two ATP-dependant efflux pumps: Pgp and MRP1. FCH would be an interesting probe for glioma imaging which would not be effluxed from the resistant cells by the classic MDR ABC transporters. Our results clearly show that FCH uptake reflects accelerated choline metabolism and is related to tumour aggressiveness and drug resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19300998     DOI: 10.1007/s00259-009-1101-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  47 in total

1.  Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines.

Authors:  T C Hour; J Chen; C Y Huang; J Y Guan; S H Lu; C Y Hsieh; Y S Pu
Journal:  Anticancer Res       Date:  2000 Sep-Oct       Impact factor: 2.480

Review 2.  Choline transport for phospholipid synthesis.

Authors:  Vera Michel; Zongfei Yuan; Shobha Ramsubir; Marica Bakovic
Journal:  Exp Biol Med (Maywood)       Date:  2006-05

3.  PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.

Authors:  Jean-Noël Talbot; Fabrice Gutman; Laetitia Fartoux; Jean-Didier Grange; Nathalie Ganne; Khaldoun Kerrou; Dany Grahek; Françoise Montravers; Raoul Poupon; Olivier Rosmorduc
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-27       Impact factor: 9.236

4.  MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.

Authors:  A van Helvoort; A J Smith; H Sprong; I Fritzsche; A H Schinkel; P Borst; G van Meer
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

5.  Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.

Authors:  T R DeGrado; R E Coleman; S Wang; S W Baldwin; M D Orr; C N Robertson; T J Polascik; D T Price
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

6.  Choline transporter as a novel target for molecular imaging of cancer.

Authors:  Toshihiko Hara; Aditya Bansal; Timothy R DeGrado
Journal:  Mol Imaging       Date:  2006 Oct-Dec       Impact factor: 4.488

7.  Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.

Authors:  M D Cordobes; A Starzec; L Delmon-Moingeon; C Blanchot; J C Kouyoumdjian; G Prévost; M Caglar; J L Moretti
Journal:  J Nucl Med       Date:  1996-02       Impact factor: 10.057

8.  Multidrug resistance in aggressive lymphoproliferative disorders of T and natural-killer origin.

Authors:  B Drénou; L Amiot; T Lamy; P Y Le Prisé; R Fauchet
Journal:  Leuk Lymphoma       Date:  1998-07

9.  Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.

Authors:  Ludwig Rinnab; Felix M Mottaghy; Norbert M Blumstein; Sven N Reske; Richard E Hautmann; Kathrin Hohl; Peter Möller; Thomas Wiegel; Rainer Kuefer; Juergen E Gschwend
Journal:  BJU Int       Date:  2007-10       Impact factor: 5.588

Review 10.  ABC multidrug transporters: structure, function and role in chemoresistance.

Authors:  Frances J Sharom
Journal:  Pharmacogenomics       Date:  2008-01       Impact factor: 2.533

View more
  5 in total

Review 1.  Imaging biomarkers in primary brain tumours.

Authors:  Egesta Lopci; Ciro Franzese; Marco Grimaldi; Paolo Andrea Zucali; Pierina Navarria; Matteo Simonelli; Lorenzo Bello; Marta Scorsetti; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-12-18       Impact factor: 9.236

2.  Perillyl alcohol: Dynamic interactions with the lipid bilayer and implications for long-term inhalational chemotherapy for gliomas.

Authors:  Clovis Orlando da Fonseca; Himanshu Khandelia; Marcela D'Alincourt Salazar; Axel H Schönthal; Osório C Meireles; Thereza Quirico-Santos
Journal:  Surg Neurol Int       Date:  2016-01-05

Review 3.  Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer Cells and Immune Cells.

Authors:  Renata de Freitas Saito; Luciana Nogueira de Sousa Andrade; Silvina Odete Bustos; Roger Chammas
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

4.  Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.

Authors:  Joo Ern Ang; Rupinder Pandher; Joo Chew Ang; Yasmin J Asad; Alan T Henley; Melanie Valenti; Gary Box; Alexis de Haven Brandon; Richard D Baird; Lori Friedman; Mika Derynck; Bart Vanhaesebroeck; Suzanne A Eccles; Stan B Kaye; Paul Workman; Johann S de Bono; Florence I Raynaud
Journal:  Mol Cancer Ther       Date:  2016-04-05       Impact factor: 6.261

5.  Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy.

Authors:  Elke Hattingen; Oliver Bähr; Johannes Rieger; Stella Blasel; Joachim Steinbach; Ulrich Pilatus
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.